186 related articles for article (PubMed ID: 16193258)
1. Minocycline in amyotrophic lateral sclerosis: a pilot study.
Pontieri FE; Ricci A; Pellicano C; Benincasa D; Buttarelli FR
Neurol Sci; 2005 Oct; 26(4):285-7. PubMed ID: 16193258
[TBL] [Abstract][Full Text] [Related]
2. [Adverse efects of riluzole (Rilutek) in the treatment of amyotrophic lateral sclerosis].
Roch-Torreilles I; Camu W; Hillaire-Buys D
Therapie; 2000; 55(2):303-12. PubMed ID: 10967703
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of riluzole in amyotrophic lateral sclerosis.
Lacomblez L; Bensimon G; Leigh PN; Debove C; Bejuit R; Truffinet P; Meininger V;
Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Mar; 3(1):23-9. PubMed ID: 12061945
[TBL] [Abstract][Full Text] [Related]
4. Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients.
Iłzecka J; Stelmasiak Z; Solski J; Wawrzycki S; Szpetnar M
Neurol Sci; 2003 Nov; 24(4):290-2. PubMed ID: 14658053
[TBL] [Abstract][Full Text] [Related]
5. [Cotreatment of amyotrophic lateral sclerosis patients].
Iwasaki Y; Ikeda K
Rinsho Shinkeigaku; 1999 Dec; 39(12):1253-5. PubMed ID: 10791091
[TBL] [Abstract][Full Text] [Related]
6. Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic lateral sclerosis? Arguments against.
Ludolph AC; Riepe MW
Neurology; 1999; 53(8 Suppl 5):S46-9; discussion S55-7. PubMed ID: 10560638
[TBL] [Abstract][Full Text] [Related]
7. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
Dib M
Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
[TBL] [Abstract][Full Text] [Related]
8. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS.
Scelsa SN; MacGowan DJ; Mitsumoto H; Imperato T; LeValley AJ; Liu MH; DelBene M; Kim MY
Neurology; 2005 Apr; 64(7):1298-300. PubMed ID: 15824372
[TBL] [Abstract][Full Text] [Related]
9. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
[TBL] [Abstract][Full Text] [Related]
10. An association study of riluzole serum concentration and survival and disease progression in patients with ALS.
Groeneveld GJ; van Kan HJ; Lie-A-Huen L; Guchelaar HJ; van den Berg LH
Clin Pharmacol Ther; 2008 May; 83(5):718-22. PubMed ID: 17898704
[TBL] [Abstract][Full Text] [Related]
11. Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002).
Zoing MC; Burke D; Pamphlett R; Kiernan MC
J Clin Neurosci; 2006 Jan; 13(1):78-83. PubMed ID: 16410201
[TBL] [Abstract][Full Text] [Related]
12. Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease.
Ishiyama T; Okada R; Nishibe H; Mitsumoto H; Nakayama C
Brain Res; 2004 Sep; 1019(1-2):226-36. PubMed ID: 15306257
[TBL] [Abstract][Full Text] [Related]
13. Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole.
Sívori M; Rodríguez GE; Pascansky D; Sáenz C; Sica RE
Medicina (B Aires); 2007; 67(4):326-30. PubMed ID: 17891927
[TBL] [Abstract][Full Text] [Related]
14. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers.
Levine TD; Bowser R; Hank N; Saperstein D
Amyotroph Lateral Scler; 2010 Dec; 11(6):514-9. PubMed ID: 20839903
[TBL] [Abstract][Full Text] [Related]
15. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.
Meininger V; Asselain B; Guillet P; Leigh PN; Ludolph A; Lacomblez L; Robberecht W;
Neurology; 2006 Jan; 66(1):88-92. PubMed ID: 16401852
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 trial of riluzole in spinal muscular atrophy.
Russman BS; Iannaccone ST; Samaha FJ
Arch Neurol; 2003 Nov; 60(11):1601-3. PubMed ID: 14623733
[TBL] [Abstract][Full Text] [Related]
17. [Tolerance of riluzole in a phase IIIb clinical trial].
Lacomblez L; Dib M; Doppler V; Faudet A; Robin V; Salachas F; Bensimon G; Meininger V
Therapie; 2002; 57(1):65-71. PubMed ID: 12090150
[TBL] [Abstract][Full Text] [Related]
18. Clinical potential of minocycline for neurodegenerative disorders.
Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
[TBL] [Abstract][Full Text] [Related]
19. [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine].
Gámez J
Neurologia; 2008 Oct; 23(8):484-93. PubMed ID: 18802797
[TBL] [Abstract][Full Text] [Related]
20. What has changed with riluzole?
Meininger V; Lacomblez L; Salachas F
J Neurol; 2000 Dec; 247 Suppl 6():VI/19-22. PubMed ID: 19714404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
